To be sure, this cancer candidate (out of legacy Schering-Plough) is a long way from being a marketable product — but we’ll keep an eye on the data, soon to trickle out of this year’s meeting of the American Society of Hematology in Orlando, Florida — just the same:
. . . .Multiple clinical studies of dinaciclib (SCH 727965) will be presented by Merck at the upcoming 52nd American Society of Hematology (ASH) Annual Meeting being held in Orlando, Florida at the Orange County Convention Center, December 4–7, 2010.
Dinaciclib is a pro-apoptotic inhibitor of cyclin-dependent kinases being evaluated by Merck for the potential treatment of cancer. In connection with Ligand’s acquisition of Pharmacopeia, dinaciclib is derived from a collaboration initiated in 1998 between Pharmacopeia and Schering-Plough Ltd. . . .
Stay tuned — but I’d be shocked if the NDA for this cancer candidate is filed with US FDA before 2015 or 2016 — and thus not likely approvable before 2016 or 2017.